A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 585-594

  Gold, Deborah T ^a   Martin, Bradley C ^b   Frytak, Jennifer R ^c   Amonkar, Mayur M ^d   Cosman, Felicia ^e,f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c i3 Innovus   (United States)

^d GLAXOSMITHKLINE   (United States)

^e HELEN HAYES HOSPITAL   (United States)

^f NewYork Presbyterian Hospital   (United States)

Author keywords

Alendronate; Bisphosphonates; Claims; Fracture risk; Medical database; Persistence

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

AGE DISTRIBUTION; AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FRACTURES, SPONTANEOUS; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947396703     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167615     Document Type: Article

References (59)

1. Melton 3rd LJ. Epidemiology worldwide. Endocrinol Metab Clin North Am 2003;32:1-13
2. Tuck SP, Francis RM. Osteoporosis. Postgrad Med J 2002;78: 526-32
3. US Congress OoTA. Hip fracture outcomes in people aged fifty and over [online]. Available from http://www.wws.princeton. edu/cgi-bin/byteserv.prl/ ~ota/disk1/1994/9413/9413.PDF [May 10, 2005]
4. Cummings SR, Black D. Should perimenopausal women be screened for osteoporosis? Ann Intern Med 1986;104: 817-23
5. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
6. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study [Study of Osteoporotic Fractures Research Group]. Arch Intern Med 1999;159:1215-20
7. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39
8. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. J Am Med Assoc 2001;285:320-3
9. Chevalley T, Hoffmeyer P, Bonjour JP, et al. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporosis Int 2002;13:450-5
10. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997;103:S20-S25
11. Body JJ. Management of primary osteoporosis. Acta Clin Belg 2002;57:277-83
12. Boonen S, Vanderschueren D. Fracture protection in osteoporosis with risedronate. Hosp Med 2004;65:535-40
13. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
14. Rozkydal Z, Janicek P. The effect of alendronate in the treatment of postmenopausal osteoporosis. Bratisl Lek Listy 2003;104:309-13
15. Sartori L, Adami S, Filipponi P, et al. Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. Aging Clin Exp Res 2003;15:271-83
16. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 2003;349: 1207-15
17. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporosis Int 2002;13:644-9
18. Stephen AB, Wallace WA. The management of osteoporosis. J Bone Jt Surg Br 2001;83:316-23
19. Cole RP, Palushock S, Haboubi A. Osteoporosis management: physicians' recommendations and womens' compliance following osteoporosis testing. Women Health 1999;29:101-15
20. Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
21. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis [The Alendronate Phase III Osteoporosis Treatment Study Group]. New Engl J Med 1995;333:1437-43
22. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-24
23. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis [Alendronate Osteoporosis Treatment Study Groups]. J Am Med Assoc 1997;277:1159-64
24. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Am Med Assoc 1998;280:2077-82
25. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. J Am Med Assoc 1999;282:1344-52
26. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Osteoporosis Int 2000;11:83-91
27. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women [Hip Intervention Program Study Group]. New Engl J Med 2001;344:333-40
28. Eichner SF, Lloyd KB, Timpe EM. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 2003;37:711-24
29. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
30. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859-62
31. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporosis Int 2003;14:259-62
32. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
33. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
34. Sunyecz J, Gallagher R, MacCosbe P. Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. The Female Patient 2006;31:21-8
35. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006;17:922-8
36. Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
37. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80: 856-61
38. Sebaldt RJ, Shane LG, Pham B, et al. Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporosis Int 2004;15: S107
39. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8
40. Finigan J, Bainbridge P, Eastell R. Adherence to osteoporosis therapies. Osteoporosis Int 2001;12:[abstract P.110]
41. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 2004;15:1003-8
42. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
43. Watts NB, Worley K, Solis A, et al. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Managed Care Pharm 2004;10:142-51
44. Watts NB. Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 2001;16:S407
45. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74: 129-35
46. Schiff I, Rebar R, Cramer J, et al. Achieving long-term continuance of menopausal ERT/HRT: Consensus Opinion of the North American Menopause Society. Menopause 1998;5: 69-76
47. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging 1998;12: 7-15
48. Prestwood KM. Osteoporosis: up-to-date strategies for prevention and treatment [Interview by Marc E. Weksler]. Geriatrics 1997;52:92-4, 7-8
49. Gallagher JC. Pathophysiology of osteoporosis. Semin Nephrol 1992;12:109-15
50. Cuddihy MT, Amadio PC, Gabriel SE, et al. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporosis Int 2004;15:695-700
51. Liel Y, Castel H, Bonneh DY. Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low-impact fractures. Osteoporosis Int 2003;14:490-5
52. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23
53. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
54. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871-86
55. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
56. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006;12:522-8
57. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
58. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26:814-23
59. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90